Skip to main content
Erschienen in: Head and Neck Pathology 1/2021

29.04.2020 | Case Reports

Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature

verfasst von: Sympascho Young, Justin Oh, Hussam Bukhari, Tony Ng, Nichole Chau, Eric Tran

Erschienen in: Head and Neck Pathology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Oligometastatic disease is a hypothesized intermediate stage of disease between localized and widespread metastatic cancer. Localized treatment of oligometastatic lesions may offer survival advantages in addition to systemic treatment. In this case report, we describe a patient who presented with small cell neuroendocrine carcinoma “Merkel type” (SNECM) of the parotid gland which had metastasized to the brain and adrenal gland. He was treated with chemotherapy followed by stereotactic radiotherapy and volumetric modulated arc therapy for oligometastasis. He maintains good functional status with low burden of disease at 20-months after diagnosis. SNECM is a rare and aggressive parotid cancer with immunohistochemical and morphologic similarities to Merkel cell carcinoma (MCC). There are only 44 cases of parotid SNECM in the English literature. This is the first case to describe management of oligometastatic SNECM and we review literature on management of both SNECM and metastatic MCC.
Literatur
1.
Zurück zum Zitat Otake S, Goto T. Stereotactic radiotherapy for oligometastasis. Cancers (Basel). 2019;11:133.CrossRef Otake S, Goto T. Stereotactic radiotherapy for oligometastasis. Cancers (Basel). 2019;11:133.CrossRef
2.
Zurück zum Zitat Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.CrossRef Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.CrossRef
3.
Zurück zum Zitat Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.CrossRef Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.CrossRef
4.
Zurück zum Zitat Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.CrossRef Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.CrossRef
5.
Zurück zum Zitat Chernock RD, Duncavage EJ. Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: salivary neuroendocrine carcinoma-an overview of a rare disease with an emphasis on determining tumor origin. Head Neck Pathol. 2018;12:13–211.CrossRef Chernock RD, Duncavage EJ. Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: salivary neuroendocrine carcinoma-an overview of a rare disease with an emphasis on determining tumor origin. Head Neck Pathol. 2018;12:13–211.CrossRef
6.
Zurück zum Zitat Kraemer BB, Mackay B, Batsakis JG. Small cell carcinomas of the parotid gland. A clinicopathologic study of three cases. Cancer. 1983;52:2115–21.CrossRef Kraemer BB, Mackay B, Batsakis JG. Small cell carcinomas of the parotid gland. A clinicopathologic study of three cases. Cancer. 1983;52:2115–21.CrossRef
7.
Zurück zum Zitat Gnepp DR, Wick MR. Small cell carcinoma of the major salivary glands. An immunohistochemical study. Cancer. 1990;66:185–92.CrossRef Gnepp DR, Wick MR. Small cell carcinoma of the major salivary glands. An immunohistochemical study. Cancer. 1990;66:185–92.CrossRef
8.
Zurück zum Zitat Fornelli A, Eusebi V, Pasquinelli G, Quattrone P, Rosai J. Merkel cell carcinoma of the parotid gland associated with Warthin tumour: report of two cases. Histopathology. 2001;39:342–6.CrossRef Fornelli A, Eusebi V, Pasquinelli G, Quattrone P, Rosai J. Merkel cell carcinoma of the parotid gland associated with Warthin tumour: report of two cases. Histopathology. 2001;39:342–6.CrossRef
9.
Zurück zum Zitat Nagao T, Gaffey TA, Olsen KD, Serizawa H, Lewis JE. Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. Am J Surg Pathol. 2004;28:762–70.CrossRef Nagao T, Gaffey TA, Olsen KD, Serizawa H, Lewis JE. Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. Am J Surg Pathol. 2004;28:762–70.CrossRef
10.
Zurück zum Zitat Jorcano S, Casado A, Berenguer J, Arenas M, Rovirosa A, Colomo L. Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clin Transl Oncol. 2008;10:303–6.CrossRef Jorcano S, Casado A, Berenguer J, Arenas M, Rovirosa A, Colomo L. Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clin Transl Oncol. 2008;10:303–6.CrossRef
11.
Zurück zum Zitat Ghaderi M, Coury J, Oxenberg J, Spector H. Primary Merkel cell carcinoma of the parotid gland. Ear Nose Throat J. 2010;89:E24–27.CrossRef Ghaderi M, Coury J, Oxenberg J, Spector H. Primary Merkel cell carcinoma of the parotid gland. Ear Nose Throat J. 2010;89:E24–27.CrossRef
12.
Zurück zum Zitat Mulder DC, Rosenberg AJWP, Storm-Bogaard PW, Koole R. Spontaneous regression of advanced Merkel-cell-like small cell carcinoma of the parotid gland. British Journal of Oral and Maxillofacial Surgery. 2010;48:199–200.CrossRef Mulder DC, Rosenberg AJWP, Storm-Bogaard PW, Koole R. Spontaneous regression of advanced Merkel-cell-like small cell carcinoma of the parotid gland. British Journal of Oral and Maxillofacial Surgery. 2010;48:199–200.CrossRef
13.
Zurück zum Zitat Chernock RD, Duncavage EJ, Gnepp DR, El-Mofty SK, Lewis JS. Absence of Merkel cell polyomavirus in primary parotid high-grade neuroendocrine carcinomas regardless of cytokeratin 20 immunophenotype. Am J Surg Pathol. 2011;35:1806–11.CrossRef Chernock RD, Duncavage EJ, Gnepp DR, El-Mofty SK, Lewis JS. Absence of Merkel cell polyomavirus in primary parotid high-grade neuroendocrine carcinomas regardless of cytokeratin 20 immunophenotype. Am J Surg Pathol. 2011;35:1806–11.CrossRef
14.
Zurück zum Zitat de Biase D, Ragazzi M, Asioli S, Eusebi V. Extracutaneous Merkel cell carcinomas harbor polyomavirus DNA. Hum Pathol. 2012;43:980–5.CrossRef de Biase D, Ragazzi M, Asioli S, Eusebi V. Extracutaneous Merkel cell carcinomas harbor polyomavirus DNA. Hum Pathol. 2012;43:980–5.CrossRef
15.
Zurück zum Zitat Kanazawa T, Fukushima N, Tanaka H, Shiba J, Nishino H, Mineta H, et al. Parotid small cell carcinoma presenting with long-term survival after surgery alone: a case report. J Med Case Rep. 2012;6:431.CrossRef Kanazawa T, Fukushima N, Tanaka H, Shiba J, Nishino H, Mineta H, et al. Parotid small cell carcinoma presenting with long-term survival after surgery alone: a case report. J Med Case Rep. 2012;6:431.CrossRef
16.
Zurück zum Zitat Fisher CA, Harms PW, McHugh JB, Edwards PC, Siddiqui J, Palanisamy N, et al. Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:703–12.CrossRef Fisher CA, Harms PW, McHugh JB, Edwards PC, Siddiqui J, Palanisamy N, et al. Small cell carcinoma in the parotid harboring Merkel cell polyomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:703–12.CrossRef
17.
Zurück zum Zitat Knopf A, Bas M, Hofauer B, Mansour N, Stark T. Clinicopathological characteristics of head and neck Merkel cell carcinomas. Head & Neck. 2017;39:92–7.CrossRef Knopf A, Bas M, Hofauer B, Mansour N, Stark T. Clinicopathological characteristics of head and neck Merkel cell carcinomas. Head & Neck. 2017;39:92–7.CrossRef
18.
Zurück zum Zitat Bizzarro T, Buda R, Ricci M, Bernardi L. Cytological diagnosis of a rare case of primary Merkel cell carcinoma of the parotid gland. Cytopathology. 2017;28:552–4.CrossRef Bizzarro T, Buda R, Ricci M, Bernardi L. Cytological diagnosis of a rare case of primary Merkel cell carcinoma of the parotid gland. Cytopathology. 2017;28:552–4.CrossRef
19.
Zurück zum Zitat Giroulet F, Tabotta F, Pomoni A, Prior J. Primary parotid Merkel cell carcinoma: a first imagery and treatment response assessment by 18F-FDG PET. BMJ Case Reports. 2019;12. Giroulet F, Tabotta F, Pomoni A, Prior J. Primary parotid Merkel cell carcinoma: a first imagery and treatment response assessment by 18F-FDG PET. BMJ Case Reports. 2019;12.
20.
Zurück zum Zitat Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497–8.CrossRef Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497–8.CrossRef
21.
Zurück zum Zitat Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016;122:50–60.CrossRef Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016;122:50–60.CrossRef
22.
Zurück zum Zitat Liang E, Brower JV, Rice SR, Buehler DG, Saha S, Kimple RJ. Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience. PLoS One. 2015;10. Liang E, Brower JV, Rice SR, Buehler DG, Saha S, Kimple RJ. Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience. PLoS One. 2015;10.
23.
Zurück zum Zitat Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077.CrossRef Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077.CrossRef
24.
Zurück zum Zitat Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016;374:2542–52.CrossRef Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016;374:2542–52.CrossRef
25.
Zurück zum Zitat Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRef Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRef
26.
Zurück zum Zitat Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.CrossRef Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.CrossRef
27.
Zurück zum Zitat Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619–26.CrossRef Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619–26.CrossRef
28.
Zurück zum Zitat Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.CrossRef Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.CrossRef
29.
Zurück zum Zitat Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295:2483–91.CrossRef Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295:2483–91.CrossRef
30.
Zurück zum Zitat Mazzola R, Corradini S, Gregucci F, Figlia V, Fiorentino A, Alongi F. Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. Front Oncol. 2019;9. Mazzola R, Corradini S, Gregucci F, Figlia V, Fiorentino A, Alongi F. Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. Front Oncol. 2019;9.
31.
Zurück zum Zitat Harary M, Kavouridis VK, Thakuria M, Smith TR. Predictors of survival in neurometastatic Merkel cell carcinoma. Eur J Cancer. 2018;101:152–9.CrossRef Harary M, Kavouridis VK, Thakuria M, Smith TR. Predictors of survival in neurometastatic Merkel cell carcinoma. Eur J Cancer. 2018;101:152–9.CrossRef
32.
Zurück zum Zitat Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4:e173501.CrossRef Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4:e173501.CrossRef
33.
Zurück zum Zitat Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial. BMC Cancer. 2019;19:816.CrossRef Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial. BMC Cancer. 2019;19:816.CrossRef
34.
Zurück zum Zitat Ahmadi Moghaddam P, Cornejo KM, Hutchinson L, Tomaszewicz K, Dresser K, Deng A, et al. Complete Spontaneous Regression of Merkel Cell Carcinoma After Biopsy: A Case Report and Review of the Literature. Am J Dermatopathol. 2016;38:e154–8.CrossRef Ahmadi Moghaddam P, Cornejo KM, Hutchinson L, Tomaszewicz K, Dresser K, Deng A, et al. Complete Spontaneous Regression of Merkel Cell Carcinoma After Biopsy: A Case Report and Review of the Literature. Am J Dermatopathol. 2016;38:e154–8.CrossRef
Metadaten
Titel
Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature
verfasst von
Sympascho Young
Justin Oh
Hussam Bukhari
Tony Ng
Nichole Chau
Eric Tran
Publikationsdatum
29.04.2020
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 1/2021
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-020-01164-w

Weitere Artikel der Ausgabe 1/2021

Head and Neck Pathology 1/2021 Zur Ausgabe

Neu im Fachgebiet Pathologie